NCT05119140View on ClinicalTrials.gov

Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

June 10, 2022

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
Ulcerative Colitis (Disorder)
Interventions
DRUG

Hydroxychloroquine

400mg of hydroxychloroquine per oral daily

DRUG

Mesalamine

the participant will maintain their current standard of care dose which can range from 1.5g to 4.8g of mesalamine per oral daily

Trial Locations (2)

10029

Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital, New York

30322

Emory University School of Medicine, Atlanta

All Listed Sponsors
collaborator

Crohn's and Colitis Foundation

OTHER

lead

Icahn School of Medicine at Mount Sinai

OTHER